Stephan Fuhrmann

6PUBLICATIONS
28CO-AUTHORS
AudiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 08, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.

Fabio Efficace, Michal Kicinski, Corneel Coens

|Oct 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.

Eva-Maria Klein, Diana Tichy, Hans J Salwender

|Jul 01, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.

Nora Liebers, Johannes Duell, Donnacha Fitzgerald

|Jan 16, 2021
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.

Lennart Lenk, Michela Carlet, Fotini Vogiatzi

|Jan 08, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher

|Jul 21, 2018
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.

Stephan Fuhrmann, Richard Schabath, Anja Möricke

Pageof 1

Frequent Collaborators

2 joint publications

Elias K Mai

2 joint publications

Hartmut Goldschmidt

1 joint publications

Marc-Andrea Baertsch

1 joint publications

Katja C Weisel